

	Placebo	Natalizumab	OR (a)	Two-sided 90% Confidence Interval	One-sided p-value (b)
Number of subjects in the MITT population	82	77			
Day 90	78 (100)	72 (100)	1.15	[ 0.71, 1.86]	0.243
0	4 ( 5)	8 ( 11)			
1	12 ( 15)	10 ( 14)			
2	12 ( 15)	10 ( 14)			
3	15 ( 19)	13 ( 18)			
4	14 ( 18)	11 ( 15)			
5	8 ( 10)	6 ( 8)			
6	13 ( 17)	14 ( 19)			

Note: The MITT population is defined as all subjects who were randomized and have received the entire infusion of study treatment.

(a) Odds ratio from a proportional-odds logistic regression model assuming a common odds ratio across all cut points of the mRS score. Covariates include baseline DWI volume (< median vs ≥ median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).

(b) P-value based on Van Elteren's test, adjusting for baseline DWI volume (< median vs ≥ median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).